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A B S T R A C T   
Purpose: Thiazide diuretics (TD) may play a role in preventing osteoporosis. The objective was to investigate the 
effects of bendroflumethiazide in combination with bisphosphonates on bone mineral density, selected blood 
parameters, blood pressure, pulse, and muscle function. 
Methods: Double-blinded, randomized, placebo-controlled interventional study in postmenopausal osteoporotic 
women over the age of 50 years consisting of four arms: 1) 24 weeks with bendroflumethiazide +24 weeks of 
washout, 2) 24 weeks with placebo +24 weeks of washout, 3) 48 weeks with bendroflumethiazide, or 4) 48 
weeks with placebo. At inclusion, participants were on oral bisphosphonates. Intervention consisted of either 
bendroflumethiazide or placebo. Dual energy X-ray absorptiometry (DXA), vertebral fracture assessment (VFA), 
quantitative CT (QCT) and selected blood parameters were acquired at baseline and at 48 weeks and Timed-Up- 
and-Go, handgrip strength, blood pressure, pulse and balance additionally at 24 weeks. 
Results: 139 postmenopausal Caucasian women over 50 years were randomized (mean age 64.7 years (SEM 0.6, 
range 51–79)). 109 (78%) completed the study. No difference in the effect of bendroflumethiazide on DXA, VFA, 
QCT, biochemistry or muscle function were found between the treatment arms. 
Conclusion: Bendroflumethiazide for 24- or 48 weeks in combination with bisphosphonates does not improve 
bone mineral density, selected blood parameters or muscle function compared to placebo combined with 
bisphosphonates. Studies with longer treatment periods and more patients are needed to further characterize the 
effects of bendroflumethiazide on bone and subpopulations that might benefit from the treatment.   
1. Introduction 
Thiazide diuretics (TD) are a class of medications commonly used as 
first line treatment for uncomplicated hypertension (Wright et al., 
2018). TD can influence bone mineral formation, osteoblast differenti-
ation, and increase calcium retention in the kidneys(Alexander and 
Dimke, 2017; Dvorak et al., 2007). Consequently, it has been suggested 
that TD might play a role in preventing osteoporosis (Cheng et al., 
2018), though the exact mechanism is not fully elucidated. Studies have 
reported higher bone mass in participants taking thiazides (Transbøl 
et al., 1982; Wasnich et al., 1983, 1995). TD have been shown to 
decrease the risk of hip fractures with 16–30% (Bokrantz et al., 2020; 
Felson et al., 1991; Puttnam et al., 2017; Rejnmark et al., 2005). Calcium 
retention induced by TD might lead to muscle function disturbances, 
such as sarcopenia, which is known to increase the risk of falls and 
fractures (Wong et al., 2019). Bisphosphonates are a commonly used 
antiresorptive treatment for osteoporosis. Co-occurrence of osteoporosis 
and hypertension is common. Hence, understanding the effects of thia-
zide diuretics on bone density, fracture risk, blood profile and possible 
interaction with bisphosphonates becomes increasingly desirable. The 
objective of the present study was to investigate the effects of the thia-
zide diuretic bendroflumethiazide on bone mineral density (BMD), 
measured using DXA and QCT in a population of postmenopausal 
women already using bisphosphonates. This allows for the comparison 
of the two bone measurement modalities. Additionally, the present 
study investigated the blood profile, and muscle function tests which 
includes Timed-Up-and-Go (TUG), handgrip strength and balance and 
orthostatic blood pressure difference. 
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2. Materials and methods 
2.1. Study design and population 
The Bone Association with Thiazide Diuretics (BONATHIAD) study 
was an investigator initiated double-blinded, randomized, placebo- 
controlled interventional study consisting of four arms. Participants 
were randomly assigned to receive either 1) 24 weeks with active +24 
weeks of washout (24 wks active), 2) 24 weeks with placebo +24 weeks 
of washout (24 wks placebo), 3) 48 weeks with active (48 wks active), or 
4) 48 weeks with placebo (48 wks placebo). The affiliation to either 
washout (group 1 and 2) or continuation of medication (group 3 and 4) 
was masked until 24 wks. Active consisted of a tablet containing 2.5 mg 
bendroflumethiazide and 573 mg potassium chloride in the form of 
Centyl® with potassium chloride (Leo Pharma A/S, Ballerup, Denmark). 
Placebo was a biologically inactive tablet containing starch and talc 
(JemoPharm A/S, Stege, Denmark). The active and placebo tablets were 
visually indistinguishable and administered orally. Participants were 
recruited from the osteoporosis clinic at Aalborg University Hospital in 
Denmark from July 2016 to March 2018. The study population included 
postmenopausal women over the age of 50 years with osteoporosis 
diagnosed using traditional dual energy x-ray absorptiometry (DXA) 
scans. All participants were treated with oral alendronate 70 mg once 
weekly prior to inclusion and throughout the study in accordance with 
Danish guidelines for osteoporosis treatment. The length of bisphosph-
onates treatment prior to inclusion for completed patients in the 24 wks 
active group was mean 2.0 years (SEM = 0.35, n = 22); the placebo 24 
wks group mean was 2.0 years (SEM = 0.34, n = 17); the active 48 weeks 
group mean was 2.1 years (SEM = 0.40, n = 30), and the placebo 48 wks 
group mean was 2.2 years (SEM = 0.32, n = 24). The total group mean 
treatment time for patients who completed was 2.1 years (SEM = 0.18, 
n = 93). Unfortunately, data was not available for 16 patients. Exclusion 
criteria included past hip- or lumbar fractures, prior diagnosis of oste-
oporosis, or prior use of thiazide-, or anabolic bone treatments. A full list 
of inclusion and exclusion criteria can be seen in the supplemental ap-
pendix. All laboratory analyses were performed in an ISO 15189 and 
DANAK accredited laboratory. 
2.2. Randomization process 
Simple randomization was performed at The Hospital Pharmacy of 
the North Denmark Region using https://www.randomizer.org. Subjects 
were assigned a randomization code and allocated to one of the study 
groups. The study medicine was prepared by The Hospital Pharmacy and 
dispensed in identical packages to ensure blinding. The packages had 
numbered labels, with each subject receiving the medication sequen-
tially in ascending order. We assessed compliance with the study 
treatment by counting the number of non-administered tablets upon 
return from the participants. 
Randomization codes and the corresponding contents were known 
only to the Pharmacy Department. Randomization codes and partici-
pants were unblinded to the investigators after the completion of the 
study. 
2.3. Study visits 
Dual energy x-ray absorptiometry (DXA), vertebral fracture assess-
ment (VFA), quantitative computed tomography (QCT), Timed-Up-and- 
Go (TUG), handgrip strength, blood pressure, pulse, and balance were 
acquired at baseline and at 48 wks. TUG, handgrip strength, blood 
pressure, pulse and balance were furthermore acquired at 24 wks. The 
study setup is displayed in Fig. S1. 
2.4. BMD measurement 
Bone mineral density (BMD) was determined using a Hologic 
Horizon A DXA-scanner (Software Version 13.6.0.5:3; S/N 200084; 
Hologic, MA, USA). Further analysis was conducted in APEX System 
Software Version 5.5.3.1 (Neptune Systems, Morgan Hill, CA, USA). 
DXA-scans were performed by experienced laboratory technicians at the 
Endocrine laboratory at Aalborg University Hospital. Quality verifica-
tion for 2017 at our facility resulted in the following estimates for 
variation for routine scan procedures: Least significance change (LSC), 
coefficient of variation (CV)% = 1.091% LSC = 3.02%; T-hip: CV% =
1.15%, LSC = 3.18%; FN: CV% = 1.77% LSC = 4.91%. BMD was 
measured using manufacturer-supplied standard methods over the 
lumbar spine (LS) L1-L4, the total hip (TH), and the femoral neck (FN), 
and results were reported as T-scores. The standard Hologic reference 
databases for Caucasian Danish women were used. BMD equipment 
underwent daily quality control and regular maintenance. 
2.5. Vertebral fracture assessment 
Immediately after BMD measurements by DXA, VFA was performed 
in the same session using the same equipment and analyzed using 
Genant’s semiquantitative method (Genant et al., 1993). Assessments 
were performed independently by PV, who was blinded to BMD, 
biochemical data, and randomization groups. Fractures were considered 
significant if more than a 20% height reduction was present. Fractures 
were graded as follows: Grade I: 20% < height reduction ≤25%; Grade 
II: 25% < height reduction ≤40%; Grade III: height reduction >40%. 
2.6. Quantitative computed tomography (QCT) 
QCT images were acquired using the GE-Discovery 750 HD, 64 slice 
CT-scanner, 2012, software v. 40 (GE Healthcare, IL, USA.) and analysis 
were conducted in QCT PRO™ software v. 5.1.3 (Mindways Software, 
Austin, TX, USA). Image acquisition and analysis was conducted ac-
cording to the manufacturer’s recommendation. BMD was measured 
using manufacture supplied standard methods over the lumbar spine L1- 
L5 and the left femoral neck. Scanners were serviced 4 times a year, and 
internal consistency checkups were performed monthly. 
2.7. Timed-Up-and-Go (TUG) 
On a “one, two, three, go!” signal subjects were asked to start from a 
sitting position in an armchair (seat height approximately 43–47 cm), 
walk three meters, turn, walk back to the chair and sit down again. Time 
was recorded manually from the “go” signal and stopped when the 
subject was sitting in the chair again. The test was repeated two times 
and the fastest time selected for further analysis. 
2.8. Handgrip strength 
Isometric handgrip strength was measured using a hand dynamom-
eter (NC70144, Procare.dk, Denmark). Each subject was instructed to 
perform maximal contraction force with their dominant hand (defined 
as their writing hand) in a seated upright position and the test hand 
pointing downwards, parallel with the trunk and unsupported. The test 
was repeated three times. The maximal strength of the three trials was 
used for further analysis. Values were provided as kg adjusted for BMI. 
2.9. Blood pressure and pulse 
Blood pressure and pulse were measured on the left arm both 
standing and sitting as a measure of orthostatic blood pressure changes. 
2.10. Balance ability 
Balance tests were performed with both legs close together on an 
elevated platform. In this study, the experiment was performed with 
open and closed eyes counted from 1 to 200 (forward) and with open 
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and closed eyes counting down the 7 table (backward) from a high 
number. Data was collected for 45 s. If participants lost balance the 
experiment was terminated. 
2.11. Statistical analysis and figures 
During the planning of the study, a power calculation was performed 
based on an expected increase in posterior–anterior BMD measured 
using DXA of 1% after 48 weeks. This increase was based on results by 
LaCroix et al. (2000). Based on the assumption of a standard error of 3%, 
risk of type-1-errors of 5% and type-2 errors of 10%, 70 subjects would 
be necessary in each of the 24- and 48 weeks subgroups. To account for 
dropouts or exclusions, we planned to include 88 patients in each sub-
group (a total of 175 patients). Our previous study showed a decrease in 
fracture occurrence after the end of treatment which is why we included 
a 24 week washout period for two groups (Kruse et al., 2016a, 2016b). 
The Shapiro-Wilk test was used as normality test. For descriptive 
analyses, parametric quantitative variables were expressed with means 
and standard error of the mean (SEM). Nonparametric quantitative 
variables were expressed with median and interquartile range. 
To investigate the association between groups, one-factor analysis of 
variance (ANOVA) with post hoc Bonferroni was used. When comparing 
the evolution of quantitative variables at different time points ANOVA 
with repeated measures, mixed effects model or a paired t-test was used. 
Missing or incomplete data were not included. All statistical analysis 
was performed in GraphPad Prism v8.00 and Excel 365. A p-value ≤0.05 
was deemed significant. Figures were made in Adobe Photoshop® CC 
2019 (Adobe, Park Avenue, San Jose, CA, USA). 
Fig. 1. 1 or 1.5 column, color: black/white. Flow chart of the participants.  
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2.12. Endpoints 
2.12.1. Primary endpoints 
The primary endpoints were absolute changes in BMD as measured 
by DXA at the lumbar spine (LS), total hip (TH), and femoral neck (FN) 
between baseline and 48 wks. 
2.12.2. Secondary endpoints 
Changes in volumetric BMD and cortical width by QCT at the LS and 
the FN between baseline and 48 wks. 
Changes in plasma(p)-potassium, p-sodium, p-ionized calcium, p- 
total albumin corrected calcium, blood urea nitrogen (BUN), p-magne-
sium, hemoglobin A1 (HbA1c), p-creatinine, and 24-h urinary calcium 
between baseline and 48 wks. 
Change in TUG in seconds measured between baseline, 24- and 48 
Table 1 
Demographic, clinical characteristics and measurements of the patients at baseline. Additional information can be found in the Supplementary Appendix. Participants 
were randomly assigned to receive either 1) 24 weeks with active +24 weeks of washout, 2) 24 weeks with placebo +24 weeks of washout, 3) 48 weeks with active, or 
4) 48 weeks with placebo. Active consisted of 2.5 mg bendroflumethiazide and 573 mg potassium chloride. Placebo was visually indistinguishable and contained starch 
and talc. Standard error of the mean (SEM). Dual X-ray absorptiometry (DXA). Bone mineral density (BMD). Quantitative computed tomography (QCT). Lumbar spine 
(LS). Total hip (TH). Femoral neck (FN).  
Parameter Active 24 weeks Placebo 24 weeks Active 48 weeks Placebo 48 weeks 
Baseline 
Mean, (SEM), [range] 
Baseline 
Mean, (SEM), [range] 
Baseline 
Mean, (SEM), [range] 
Baseline 
Mean, (SEM), [range] 
Demographics and clinical characteristics 
Age, yr 63.7, (1.5), [53–78] 65.0, (1,3), [57–77] 65.1, (1.0), [51–77] 64.9, (1.1), [51–79] 
Age of menopause, yr 48.9, (1.0), [39–56] 48.7, (1.1), [39–57] 48.0, (1.0), [33–56] 48.0, (0.9), [38–56] 








Comorbidities and additional diagnoses, n (%) 
Medication for diabetes 0 (0) 0 (0) 0 (0) 1 (3) 
Medication for hypokalemia 1 (4) 0 (0) 0 (0) 0 (0) 
Medication for hyperkaleamia 0 (0) 0 (0) 0 (0) 0 (0) 
Medication for hypokaleamia 1 (4) 0 (0) 0 (0) 1 (3) 
Medication for hyponatriæmia 2 (9) 0 (0) 1 (3) 1 (3) 
Medication for hypomagnesiæmi 0 (0) 0 (0) 4 (11) 1 (3) 
Medication for hypermagnesiæmi 0 (0) 0 (0) 0 (0) 1 (3) 
Medication for hypercholesterolæmia 1 (4) 0 (0) 6 (17) 1 (3) 
Medication for hypercalcemia 0 (0) 0 (0) 0 (0) 2 (6) 
Medication for hypertension 2 (9) 4 (24) 4 (11) 4 (12) 
Medication for pain 1 (4) 2 (12) 3 (9) 5 (12) 
Thyroid dysfunction 2 (9) 0 (0) 4 (11) 1 (3) 
Past fracture (not in lumbar or hip region) 2 (9) 2 (12) 0 (0) 0 (0) 
Past or present malignant disease 2 (4) 0 (0) 5 (14) 3 (9) 
None 6 (26) 3 (18) 7 (20) 5 (15)  
Imaging measurements 
DXA LS-BMD, g/cm2 0.73, (0.015) 0.77, (0.21) 0.78, (0.019) 0.76, (0.012) 
DXA LS-T-score − 2.9, (0.1) − 2.5, (0.2) − 2.5, (0.2) − 2.7, (0.1) 
DXA TH-BMD, g/cm2 0.72, (0.017) 0.72, (0.020) 0.74, (0.010) 0.74, (0.014) 
DXA TH-T-score − 1.8, (0.1) − 1.9, (0.7) − 1.7, (0.08) − 1.7, (0.1) 
DXA FN-BMD, g/cm2 0.60, (0.015) 0.60, (0.024) 0.61, (0.012) 0.61, (0.014) 
DXA FN-T-score − 2.2, (0.1) − 2.2, (0.20) − 2.1, (0.1) − 2.1, (0.1) 
QCT LS-BMD, mg/cm3 92.01, (6.18) 76.26, (3.83) 81.37, (2.74) 79.34, (3.79) 
QCT LS-T-score − 2.9, (0.2) − 3.5, (0.2) − 3.3, (0.1) − 3.4, (0.2) 
QCT FN-BMD, mg/cm3 0.72, (0.20) 0.70, (0.024) 0.72, (0.014) 0.72, (0.018) 
QCT FN-T-score − 1.8, (0.2) − 1.9, (0.2) − 1.7, (0.1) − 1.7, (0.2)  
Bloodtests 
P-Potassium (K), mmol/l 3.9, (0.07) 4.0, (0.05) 3.9, (0.04) 3.9, (0.05) 
P-Sodium (Na), mmol/l 140.5, (0.6) 140.2, (0.5) 140.7, (0.3) 140.4, (0.5) 
P-Calcium ionized (Adjusted for pH 7.4), mmol/l 1.2, (0.007) 1.2, (0.01) 1.2, (0.007) 1.2, (0.01) 
P-Total albumin corrected calcium, mmol/l 2.4, (0.02) 2.4, (0.02) 2.4, (0.01) 2.4, (0.02) 
Blood urea nitrogen, mmol/l 0.3, (0.01) 0.3, (0.02) 0.2, (0.008) 0.3, (0.01) 
P-Magnesium, mmol/l 0.9, (0.02) 0.8, (0.02) 0.9, (0.01) 0.8, (0.008) 
Hemoglobin A1c, mmol/mol 34.8, (0.7) 33.7, (0.5) 35.3, (0.4) 35.0, (0.6) 
P-Creatinine, μmol/l 65.0, (2.0) 67.0, (2.7) 64.8, (1.7) 67.7, (1.7)  
Blood pressure, handgrip strength and timed up and go 
Timed-Up-and-Go, seconds 6.7, (0.3) 7.0, (0.3) 6.6, (0.23) 7.6, (0.45) 
Handgrip strength, kPa 26.7, (0.9) 25.3, (1.3) 26.9, (1.1) 25.3, (1.2) 
Systolic blood pressure. Delta value between standing and sitting. 
mmHg 
− 4.6, (1.9) − 3.1, (2.0) − 1.2, (1.8) − 3.1, (2.3) 
Diastolic blood pressure. Delta value between standing and sitting, 
mmHg 
4.9, (1.1) − 1.0, (5.3) 5.5, (1.1) 5.5, (1.2) 
Pulse. Delta value between standing and sitting, beats/min 7.5, (1.0) 8.9, (1.4) 7.9, (0.9) 7.9, (1.1)  
Balance 
Eyes Open Forward, counts 95.0, (4.1) 85.0, (3.3) 85.5, (3.8) 77.9, (3.1) 
Eyes Closed Forward, counts 94.1, (4.5) 84.8, (3.1) 81.3, (3.6) 76.4, (2.8) 
Eyes Open Backwards, counts 13.1, (1.2) 13.8, (1.0) 12.2, (1.1) 12.6, (1.5) 
Eyes Closed Backwards, counts 12.7, (1.2) 14.3, (1.1) 13.0, (0.9) 11.8, (1.4)  
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wks. 
Absolute change in the difference between handgrip strength in kPa 
between baseline, 24- and 48 weeks. 
Change in the difference between standing and sitting systolic- and 
diastolic blood pressure in mmHg and pulse in beats/min between 
baseline, 24- and 48 weeks. 
Change in the difference between eyes open forward (EOF), eyes 
closed forward ECF, eyes open backwards (EOB), eyes closed backwards 
(ECB) measured in counts between baseline, 24- and 48 weeks. 
Safety endpoints are listed in the supplemental appendix. 
3. Results 
3.1. Demographics of the study subjects 
The study flow chart is shown in Fig. 1. A total of 139 post-
menopausal Caucasian women over 50 years were randomized to 
participate in this clinical trial. 109 (78%) completed the study. In total, 
23 participants were assigned to 24 wks active, 17 to 24 wk. placebo, 35 
to 48 wk. active, and 34 to 48 wk. placebo. Adherence to study medi-
cation among participants in the 24 wks active group was median 96% 
(IQR = 42%–100%), the 24 wks placebo group median was 99% (IQR =
95%–100%), the 48 wks active group median was 96% (IQR = 51%– 
99%), and the 48 wks placebo group median was 97% (IQR = 91%– 
99%). 
Characteristics of the subjects at baseline are listed in Table 1. An 
additional list of baseline demographic and clinical characteristics can 
be seen in Supplemental Table S1. In summary, the mean age of the 
study population was 64.7 years (yrs) (SEM = 0.6, range = 51–79 yrs) 
and the average age of menopause was 48.3 yrs. (SEM = 0.5, range =
33–57 yrs). The mean height was 163.4 cm (SEM = 0.5, range =
150.5–176 cm) and the average weight was 65.0 kg (SEM = 1.0, range =
46.6–105 kg). 
Table 2 
Δ-value of results from DXA and QCT between baseline and 48 weeks. Additional information including Z-scores and BMC values are available in the Supplementary 
Appendix. 
Participants were randomly assigned to receive either 1) 24 weeks with active +24 weeks of washout, 2) 24 weeks with placebo +24 weeks of washout, 3) 48 weeks 
with active, or 4) 48 weeks with placebo. Active consisted of 2.5 mg bendroflumethiazide and 573 mg potassium chloride. Placebo was visually indistinguishable and 
contained starch and talc 
a (active 24 weeks compared to placebo 24 weeks, b (active 24 weeks compared to active 48 weeks), c (placebo 24 weeks compared to placebo 48 weeks), d (active 48 
weeks compared to placebo 48 weeks). Bold and underlined indicates statistical significance. 
Standard error of the mean (SEM). Number (n). Dual X-ray absorptiometry (DXA). Bone mineral density (BMD). Quantitative computed tomography (QCT). Lumbar 
spine (LS). Total hip (TH). Femoral neck (FN).  
Parameter Active 24 weeks Placebo 24 weeks Active 48 weeks Placebo 48 weeks P-score of Δ 
value  
Δ Value, (SEM), 
percent change 
P-score Δ Value, (SEM), 
percent change 
P-score Δ Value, (SEM), 
percent change 
P-score Δ Value, (SEM), 
percent change 
P-score  




0.0639 0.015, (0.0087), 
2.6%  
0.1054 0.020, (0.0060), 2.5%  0.0019 0.016, (0.0055), 
1.3%  












0.0343 0.012, (0.0039), 
1.4%  
0.0098 0.0066, (0.0096), 
1.4%  
0.0010 0.011, (0.0028), 
1.3%  
0.0007 a≥ 0.9999 
b≥ 0.9999 
c≥ 0.9999 
d = 0.8579 
DXA TH-T-score 0.07, (0.03)  0.0156 0.09, (0.03)  0.0063 0.05, (0.02)  0.0023 0.1, (0.02)  0.0005 a≥ 0.9999 
b≥ 0.9999 
c≥ 0.9999 





0.0639 0.016, (0.0034), 
3.3%  
0.0002 − 0.00035, (0.0046), 
− 0.07%  
0.9411 0.012, (0.0040), 
1.6%  
0.0071 a = 0.3194 
b = 0.1747 
c = 0.5391 
d = 0.0273 
DXA FN-T-score 0.07, (0.04)  0.1064 0.1, (0.03)  0.0003 − 0.003, (0.04)  0.9306 0.1, (0.04)  0.0074 a≥ 0.9999 
b = 0.8895 
c≥ 0.9999 
d = 0.0835 
QCT LS-BMD, 
mg/cm3 
− 3.64, (2.68), 
− 4.0%  
0.1964 − 2.08, (2.46), 
− 2.7%  
0.4129 3.26, (1.63), 4.1%  0.0560 − 3.55, (2.01), 
− 4.4%  
0.0895 a≥ 0.9999 
b = 0.1101 
c≥ 0.9999 
d = 0.0446 






0.011, (0.019), 1.4%  0.5716 0.0093, (0.0096), 
1.4%  
0.3490 0.0059, (0.010), 0.8%  0.5631 0.0022, (0.018), 
1.4%  




QCT FN-T-score 0.09, (0.2)  0.5792 0.08, (0.08)  0.3516 0.05, (0.09)  0.5652 − 0.07, (0.1)  0.5623 a≥ 0.9999 
b≥ 0.9999 
c≥ 0.9999 
d≥ 0.9999  
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3.2. DXA, QCT and VFA 
Baseline results from DXA and QCT is seen on Table 1. Table 2 shows 
the %-change values for each group. The full comparison including in-
dividual BMC can be found on Supplemental Table S2. 
3.2.1. DXA 
A significant difference in the delta value between baseline and week 
48 was observed for FN-BMD between the 48 wks active (− 0.00035 g/ 
cm2, SEM = 0.0046, − 0.07%) and 48 wks placebo group (0.012 g/cm2, 
SEM = 0.0040, 1.6%), (p = 0.0273). No other significant difference in 
delta values between other groups or DXA indices were found. 
3.2.2. QCT 
A significant difference in the delta values between baseline and 
week 48 was observed for LS-BMD between 48 wks active (mean = 3.26 
mg/cm3, SEM = 1.63, 4.1%), compared to 48 wks placebo (mean =
− 3.55 mg/cm3, SEM = 2.01, − 4.4%), (p = 0.0446). None of the QCT 
BMD measurements were statically different between baseline and week 
48 and no other significant differences between the delta values for any 
of the groups were found. 
3.2.3. VFA 
A total of 2 patients (24 wks placebo = 1, 48 wks placebo = 1) had 
vertebral fractures as assessed by VFA. Both were present at baseline, 
and no new fractures had occurred at the end of the study. Both had a 
single vertebral fracture. Both fractures were grade 1. 
3.3. Blood tests 
Baseline results from blood tests can be found in Table 1. Table 3 
shows the delta values for each group. The full dataset can be seen on 
Supplemental Table S3. In summary, we observed no significant dif-
ference in the delta values between any of the groups. 
3.4. TUG, handgrip strength, and blood pressure- and pulse difference 
Baseline results from TUG, handgrip strength and blood pressure can 
be found on Table 1. The full dataset can be found on Supplemental 
Table S4. No significant differences were observed in delta values be-
tween any of the treatment groups. 
3.5. Balance ability 
Full balance values can be seen on Table S5. The 48 wks active group 
experienced a larger increase in the difference between baseline and 48 
weeks in EOF (mean = 9.5 s, SEM = 3.8, p = 0.0350) and ECF (mean =
10.8, SEM = 3.5, p = 0.0399) compared to the 24 wks active group 
(mean = − 5.1, SEM = 2.6 and mean = − 4.1, SEM = 2.9, respectively). 
This development, however, was not significantly different from 
development in the placebo groups. 
3.6. Adverse events 
A total of 7 serious adverse events were reported throughout this 
trial. Neither fatal events nor suspected fatal events due to study treat-
ment was seen. A list of reported serious symptoms/adverse events can 
be found in the Supplementary Appendix. 
4. Discussion 
This study tested whether bendroflumethiazide in combination with 
bisphosphonates affected BMD, fracture risk, selected blood parameters, 
TUG, handgrip strength, blood pressure difference, pulse, and balance 
ability. 
For a majority of the DXA indices an anticipated increase in BMD was 
observed. For FN-DXA BMD a small decrease in the delta value for the 48 
wks active group was observed which was significantly different 
compared to the delta value for the 48 wks placebo group. Previous 
studies have found the regular use of TD to be associated with increased 
BMD (Bauer et al., 1993; Morton et al., 1994; Wasnich et al., 1983). A 
randomized study by Bolland et al. including 122 postmenopausal 
women with osteoporosis found a significant increase of 0.9% in total 
body density after four years of treatment compared with placebo (p ≤
0.001). However, in the same study no significant between-groups dif-
ferences in femoral neck and lumbar spine was observed (Bolland et al., 
2007). Arrabal-Polo et al. found that adding a thiazide diuretic in 
addition to bisphosphonate treatment resulted in improved BMD after 2 
years of treatment pointing to an additive effect. When comparing the 
bisphosphonate group with the combination groups this increase was 
from − 1.3 to − 0.6 for hip BMD T-score, − 1.5 to − 1 for FN-BMD T-score 
and − 2.2 to − 1.4 for LS-BMD T-score (Arrabal-Polo et al., 2013). In a 3- 
year randomized, double-blinded trial among 320 (205 women, 115 
men) normotensive patients LaCroix et al. found a 1.04% increase in 
anterior posterior spine density, and 0.92% increase in hip density 
compared to placebo. No change in total-body BMD was observed 
(LaCroix et al., 2000). Given our study’s relatively short treatment 
period of 48 weeks compared to other studies one could speculate that a 
longer treatment period may lead to a larger positive increase in BMD. 
This is further substantiated by our previous study which showed that 
continued use of thiazides is more important for fracture prevention 
than dose and lifetime accumulation, and that fracture risk is decreased 
with increasing length of thiazide use duration (Kruse et al., 2016a, 
2016b). 
As far as we know, this was the first study to the use QCT to measure 
BMD after bendroflumethiazide treatment. QCT images are a superior 
modality due to the three-dimensional character of the images, which 
allows for volumetric BMD measurement of the trabecular vertebral 
bone. This also circumvents the effects of extraosseous calcification 
known to artificially raise DXA spine BMD measurements (Yu et al., 
2012). We found an increase in LS-BMD of 4.1% in the active 48 wks 
group which was significantly different from the delta value of the 
placebo 48 wks group. Interestingly, however, none of the QCT mea-
surements for any of the treatment arms were significantly changed 
between baseline and 48 weeks, which contrasts the DXA 
measurements. 
Concerning fracture prevention, several studies found 30–50% re-
ductions in the hip fracture risk in patients on thiazide therapy (Felson 
et al., 1991; Puttnam et al., 2017; Rejnmark et al., 2005). A study con-
ducted on 376,061 Medicare beneficiaries found that TD reduced the 
risk of all fractures (HR = 0.85, 95% CI = 0.76–0.97). A prospective 
cohort study conducted on 7891 individuals of 55 years or older found 
that the risk of hip fractures was significantly reduced after only 1 year 
of continuous thiazide use with a hazard ratio of 0.46 (95% CI, 0.21 to 
0.96) (Schoofs et al., 2003). However, a systematic review of published 
cohort studies found no effect of thiazides on the risk of osteoporotic 
fracture (Wang et al., 2019). In this study, we found no difference in 
fracture risk between treatment and placebo groups measured using 
VFA, though the timeframe was short and the patient sample low in this 
aspect. It should be considered that both drug-induced hyper- and hy-
potension can lead to falls and subsequent fractures. Consequently, tight 
regulation of the blood pressure is important. We consequently also 
tested whether bendroflumethiazide had any effect on the blood pres-
sure- and pulse difference, however no difference was observed. 
Inappropriate diuretic usage can lead to an increase in fall risk due to 
hypovolemia and electrolyte disturbances; affecting muscle function 
(Wehling, 2013). TD are known to cause disturbances in electrolytes, 
most importantly hyponatremia and hypokalemia (Arampatzis et al., 
2013; Clayton et al., 2006; Rejnmark et al., 2001), but also hypo-
magnesaemia (Kieboom et al., 2018). For the blood profile no differ-
ences in delta values between the groups were found. 
In this study we used TUG, handgrip strength and balance tests as a 
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Table 3 
Δ-value of blood tests, Timed-Up-and-Go, handgrip strength, blood pressure, pulse and balance between baseline and 48 weeks. Participants were randomly assigned 
to receive either 1) 24 weeks with active +24 weeks of washout, 2) 24 weeks with placebo +24 weeks of washout, 3) 48 weeks with active, or 4) 48 weeks with placebo. 
Weeks with active +24 weeks of washout, 2) 24 weeks with placebo +24 weeks of washout, 3) 48 weeks with active, or 4) 48 weeks with placebo. Active consisted of 
2.5 mg bendroflumethiazide and 573 mg potassium chloride. Placebo was visually indistinguishable and contained starch and talc. Bold and underlined indicates 
statistical significance.  
Parameter Active 24 weeks Placebo 24 weeks Active 48 weeks Placebo 48 weeks P-score of Δ value 
between baseline 




P-score Δ value, 
(SEM), percent 
change 
P-score Δ value, 
(SEM), percent 
change 




P-Potassium (K), mmol/l − 0.1, (0.1), 
− 2.6%  
0.3414 0.1, (0.06), 
2.5%  
0.0730 − 0.1, (0.06), 
− 2.6%  
0.1183 − 0.004, (0.07), 
− 0.08%  




P-Sodium (Na), mmol/l 0.4, (0.6), 
0.3%  
0.5218 0.2, (0.4), 
0.1%  
0.5939 − 0.08, (0.6), 
− 0.07%  
0.8823 − 0.1, (0.4), 
− 0.4%  





(Adjusted for pH 7.4), 
mmol/l 
− 0.004, 
(0.01), − 0.3%  
0.6748 − 0.02, (0.01), 
− 0.8%  
0.1754 − 0.01, 
(0.007), 
− 1.6%  
0.0689 0.008, (0.007), 
0.8%  
0.3117 a≥ 0.9999 
b≥ 0.9999 
c = 0.2652 
d = 0.2052 




0.9799 − 0.02, (0.02), 
− 0.6%  
0.4202 0.02, (0.02), 
0.7%  
0.2506 − 0.003, (0.02), 
− 0.4%  








0.5647 0.006 (0.01), 
2.4%  
0.3381 0.03, (0.007), 
8.0%  
0.0010 0.005, (0.007), 
1.8%  
0.5376 a≥ 0.9999 
b = 0.2725 
c≥ 0.9999 
d = 0.1098 
P-Magnesium (Mg), 
mmol/l 
− 0.02, (0.02), 
− 2.4%  
0.3115 0.02, (0.01), 
2.4%  
0.1159 0.009, (0.009), 
1.2%  
0.3341 0.02, (0.006), 
2.4%  
0.0047 a = 0.1561 







0.1405 1.0, (0.5), 
3.0%  
0.0447 1.1, (0.3), 
3.1%  




P-Creatinine, μmol/l − 2.2, (1.7), 
− 3.4%  
0.2092 1.5, (1.5), 
2.0%  
0.3299 − 1.2, (1.5), 
− 1.8%  
0.4150 1.1, (1.4), 1.6%  0.4291 a = 0.6113 
b≥ 0.9999 
c≥ 0.9999 
d = 0.9598 
24-Hour urinary calcium, 
mmol/l 
− 0.07, (0.2), 
− 2.2%  
0.7773 0.1, (0.2), 
5.0%  
0.6468 − 0.4, (0.2), 
− 16%  
0.0229 0.1, (0.2), 3.8%  0.6556 a≥ 0.9999 
b = 0.9518 
c≥ 0.9999 
d = 0.1943  





>0.9999 − 0.033, (0.2), 
− 0.5%  
>0.9999 − 0.11,(0.1), 
− 1.7%  
>0.9999 − 0.60, (0.2), 
− 7.9%  
0.0768 a = 0.7385 
b = 0.3579 
c≥ 0.9999 
d≥ 0.9999 
Handgrip strength, kPa 0.2, (0.5), 
0.7%  
>0.9999 − 1.1, (0.7), 
− 4.5%  
0.4404 − 1.9, (0.4), 
− 7.1%  
0.0007 3.1, (1.0), 7.9%  0.0412 a≥ 0.9999 
b≥ 0.9999 
c = 0.0989 
d = 0.0800 
Orthostatic systolic blood 
pressure difference, 
mmHg 
− 1.0, (2.9), 
− 22.7%  
>0.9999 1.1, (5.0), 
36.9%  
>0.9999 − 0.3, (2.4), 
− 22.7%  
>0.9999 − 3.0, (1.9), 
− 100.3%  









0.5950 − 0.3, (2.9), 
− 6.1%  
>0.9999 0.1, (1.7), 
1.4%  
>0.9999 − 3.6, (2.1), 
− 65.6%  
0.3034 a≥ 0.9999 
b≥ 0.9999 
c = 0.9776 
d = 0.4262 
Pulse. Delta value 




>0.9999 0.2, (1.7), 
2.1%  
>0.9999 − 0.04, (1.4), 
− 0.5%  
>0.9999 − 0.5, (1.0), 
− 6.4%  
>0.9999 a≥ 0.9999 
b≥ 0.9999 
c≥ 0.9999 
d≥ 0.9999  
Balance 
Eyes open forward, 
seconds 
− 5.1, (2.6), 
− 5.7%  
0.2196 − 1.9, (2.7), 
− 2.2%  
>0.9999 7.4, (2.4), 
8.1%  
0.0191 9.5, (3.8), 
10.9%  
0.0804 a≥ 0.9999 
b ¼ 0.0350 
c≥ 0.9999 
d = 0.2506 
(continued on next page) 
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proxy for muscle function, mobility, walking ability, balance, and fall 
risk. For balance tests, the 48 wks active group saw an increase in EOF 
and ECF compared to the 24 wks active group which, contrarily, saw a 
decrease. However, no difference was observed compared to the placebo 
groups. For TUG and handgrip strength no difference in delta values 
between treatment arms were observed. To our knowledge, this is the 
first time these assessments have been included to test the efficacy of 
bendroflumethiazide in relation these parameters. 
4.1. Strengths and limitations 
The double-blinded randomized controlled trial setup is the main 
strength of our study. 
However, the study also has some limitations. Firstly, the study 
period was short compared to other studies. In future, longer studies 
might be needed to further characterize the potential improvement that 
bendroflumethiazide has on bone density. Secondly, we did not consider 
supplementary medication used by patients such as vitamin D or cal-
cium supplements. Additionally, dietary patterns were not logged. 
Thirdly, we did not reach the number of patients specified in the power 
calculation due to dropout and patient exclusion. Finally, study partic-
ipants included only Caucasian Danish women and therefore it is unclear 
whether the study findings can be generalized to other racial and ethnic 
groups. Most studies on the effects of TD on osteoporosis and fractures 
have been conducted on women and it has been suggested that women 
may be more susceptible to osteoporosis and fractures (Bokrantz et al., 
2017). Therefore, other studies should be conducted to test the effect of 
bendroflumethiazide on additional subpopulations. 
5. Conclusions 
In conclusion, we found no clear evidence that thiazide therapy in-
fluences BMD in addition to oral bisphosphonates in postmenopausal 
women with osteoporosis. Further studies in larger patient cohorts are 
needed to further clarify the effect that thiazide diuretics may have on 
BMD. We furthermore encourage that the results provided herein are 
included in future metanalyses. The ageing of the population will 
constitute an increased disease burden due to fractures and thus effec-
tive prophylactic medications are desirable. The results presented in this 
study does not support using bendroflumethiazide as osteoporosis- or 
fracture treatment in addition to bisphosphonates. It is unclear whether 
combination treatment might have certain beneficial effect when used 
for longer than 48 weeks. Additional studies are also needed to stratify 
patients that may experience beneficial improvements of BMD and 
secondary parameters and those who may suffer from the usage of 
bendroflumethiazide. 
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Table 3 (continued ) 
Parameter Active 24 weeks Placebo 24 weeks Active 48 weeks Placebo 48 weeks P-score of Δ value 
between baseline 




P-score Δ value, 
(SEM), percent 
change 
P-score Δ value, 
(SEM), percent 
change 
P-score Δ value, (SEM), 
percent change 
P-score  
Eyes closed forward, 
seconds 
− 4.1, (2.9), 
− 4.3%  
0.5146 − 1.0, (3.4), 
− 1.2%  
>0.9999 6.7, (2.6), 
7.1%  
0.0556 10.8, (3.5), 
14.1%  
0.0268 a≥ 0.9999 
b ¼ 0.0399 
c≥ 0.9999 
d≥ 0.9999 
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0.0273 3.1, (0.7), 
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b≥ 0.9999 
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6.2%  
0.7348 2.9, (0.5), 
22.4%  
0.0001 2.4, (0.6), 
20.4%  




a (Active 24 weeks compared to placebo 24 weeks). b (Active 24 weeks compared to active 48 weeks). c (Placebo 24 weeks compared to placebo 48 weeks). d (Active 
48 weeks compared to placebo 48 weeks). Standard error of the mean (SEM). 
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